WEAVER GREGORY L 4

What Happened
Gregory L. Weaver, Chief Financial Officer of Altimmune, acquired 5,000 shares on March 6, 2026. The Form 4 lists the transaction as a purchase (SEC code P) at $3.54 per share, for a total cost of $17,700. This was a direct share purchase (listed as "open market or private purchase" on the filing).

Key Details

• Transaction date: 2026-03-06; Filing date: 2026-03-09 (timely filed within SEC reporting window).
• Price per share: $3.54; Total value: $17,700.
• Transaction type: Purchase (SEC code P) — filing describes "open market or private purchase" but does not specify which.
• Shares owned after transaction: Not specified in the Form 4.
• Footnotes/notable items: No 10b5-1 plan, tax withholding, or option exercise noted on the filing.

Context
Insider purchases are often of interest because they show executives putting personal capital into the company, but filings do not reveal the buyer’s motives. This was a straightforward equity purchase (not an option exercise, gift, or tax-related withholding). The Form 4 appears to have been filed on time.